Time for an update. I think the Corona crisis might have been the necessary push for the stock markets. Everyrhing was priced way to high and now finally we can buy some stock at normal prices. ETF Trading makes it all worth while. Because there is a lot of volatility…
It has been a while. So it is time for a new update. So far we had the corona crisis but the rebound from it is quite spectacular.
It was a very exciting year but in the end we could have just bought an index tracker. That would have saved me a lot of transaction costs. Only my broker got rich in the end of the year.
I made a few huge mistakes in the last month of the year. And all my profits vaporized in one month time. We call it learning money. Money you pay to learn from your mistakes.
One of my favorite stock for 2017 has to be Shopify (NYSE:SHOP). Since it’s IPO in may 2015 the stock has gone up 250% And rumor is that facebook and other big tech companies are looking to buy them. One of the biggest disadvantages for me is that they do…
All in all a really nice return in the end. It’s been a rough ride but in the end payed of pretty nice.
Usually we do not discuss politics here but this time we will make an exception. America keeps amazing me. Every time they have to choose a president they never go for the save choice, that inspires me. After they had choosen the first black president in history, who performed exceptionally…
Since I have gotten my girlfriend involved in stock trading (and the fact that I believe that my porto will be a welcome addition to my pension later). We have tried to find some long term stocks that we both feel comfortable with. They say do not buy anything that…
Whenever one of my biotech companies have good news. It almost always makes me smile. Yesterday it was GW. The shares of GW Pharmaceuticals (GWPH) are soaring on news that its cannabis-derived drug significantly diminished the seizure amount in children with a rare form of epilepsy in a phase-three trial. Epidiolex…
Maybe I’m a little late. But in december Nektar announced the following: Nektar Therapeutics (NASDAQ:NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety of NKTR-214 in the treatment of solid tumors. NKTR-214 is a novel CD122-biased cytokine designed to preferentially activate…
